Emerging research continues to spotlight the potential role of diet in cancer prevention, with olive oil—a cornerstone of the Mediterranean diet&mdas | Drug Discovery And Development ...

Intas Pharmaceuticals has received approval from the Subject Expert Committee (SEC), functioning under the Central Drugs ...

Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...

Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...

Abstract:        Obesity, a growing global issue, has been closely associated with an increased risk of various cancers, especially breast cancer. El ...

B lymphocytes exhibit dual roles in tumorigenesis, acting as both allies and adversaries in the tumor microenvironment (TME).

Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-1418, a Potential Best-in-Class, Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate ...

Explore how cutting-edge agents like alpelisib, capivasertib, MEK and ERK inhibitors, and JAK inhibitors are reshaping the treatment landscape across subtypes.

The Itovebi (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced breast ...

Department of Breast Surgery, The Affliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi, China Brain metastasis in breast cancer ... and HER2-positive subtypes. It involves complex ...

Figure 1: Key signaling pathways and targeted factors ... several major pathways involved in breast cancer, including PI3K/Akt/mTOR, RAS/RAF/MEK/ERK, HER2, Wnt/β-catenin, Notch, NF-κB, and ...

The review highlights how certain gene mutations and disrupted signaling pathways influence ... involved in breast cancer, including PI3K/Akt/mTOR, RAS/RAF/MEK/ERK, HER2, Wnt/β-catenin, Notch ...